Carmofur

• Description :

  Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA) . Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI) [1][2][3].

• Product Name Alternative :

  HCFU

• UNSPSC :

  12352005

• Hazard Statement :

  H301, H361

• Target :

  Ceramidase; FAAH; Glutathione Peroxidase; Nucleoside Antimetabolite/Analog; SARS-CoV; Virus Protease

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Neuronal Signaling

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/carmofur.html

• Purity :

  99.95

• Solubility :

  DMSO : 83.33 mg/mL (ultrasonic)

• Smiles :

  O=C(N(C(N1)=O)C=C(F)C1=O)NCCCCCC

• Molecular Formula :

  C11H16FN3O3

• Molecular Weight :

  257.26

• Precautions :

  H301, H361

• References & Citations :

  [1]Jin Z, et al. Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol. 2020 Jun;27 (6) :529-532.|[2]Realini N, Solorzano C, Pagliuca C, et al. Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity[J]. Scientific reports, 2013, 3 (1) : 1035.|[3]Wu K, et al. A new use for an old drug: carmofur attenuates lipopolysaccharide (LPS) -induced acute lung injury via inhibition of FAAH and NAAA activities[J]. Frontiers in pharmacology, 2019, 10: 818.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [61422-45-5]